Boundless Bio, Inc. Share Price

Boundless Bio, Inc. Share Price

NASDAQ: BOLD | Micro Cap
$2.53
+$0.04 (1.61%) Last updated on 29 Oct, 2026 | 20:21 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Boundless Bio, Inc. Stock Performance

Open
$2.50
Prev. Close
$2.49
Circuit Range
N/A
Day Range
$2.50 - $2.53
Year Range
$0.98 - $3.12
Volume
200
Average Traded
$2.52

Boundless Bio, Inc. Share Price Today

As of 29 October 2026, Boundless Bio, Inc.'s share price is $2.53. The stock opened at $2.50, compared to its previous close of $2.49. During today's trading session, Boundless Bio, Inc.'s share price traded between $2.50 and $2.53, with an average price of $2.51. Over the past 52 weeks, the stock has recorded a high of $3.12 and a low of $0.98. In terms of performance, Boundless Bio, Inc.'s share price has risen by 73.88% over the last six months and is up 84.67% on a year-on-year basis.

Boundless Bio, Inc. Share Price Chart

Line chart of the Boundless Bio, Inc. price trend over the selected period. The price rose overall, ranging from 2.50 to 2.53, ending at 2.53.
$2.50$2.53
L
Show Current Price
H

Boundless Bio, Inc. Stock Fundamentals & Key Indicators

Market Cap
$56.57M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-2.77
Revenue (TTM)
$0.00
Return On Equity (TTM)
-97.02%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-70.68%

Boundless Bio, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$13.88-$12.89-$13.56-$23.69
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A7.13%-5.20%-74.71%

Boundless Bio, Inc. Annual Profit & Loss

All figures in USD

Particulars20242025
Revenue$0.00$0.00
Net Profit-$65.36-$58.20
Net Profit MarginN/AN/A
Income ChangeN/A10.95%

About Boundless Bio, Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Boundless Bio, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$2.59
$2.53
+2.22%
Sep 2026
$2.81
$2.48
-14.06%
Aug 2026
$2.51
$2.88
+15.66%
Jul 2026
$2.50
$2.49
-0.60%
Jun 2026
$1.46
$2.50
+71.58%
May 2026
$1.51
$1.46
+0.34%
Apr 2026
$1.14
$1.46
+31.08%
Mar 2026
$1.13
$1.11
-4.31%
Feb 2026
$1.14
$1.16
+0.87%
Jan 2026
$1.22
$1.15
-3.36%
Dec 2025
$1.17
$1.19
+3.03%
Nov 2025
$1.28
$1.16
-15.69%

BOLD Share Price FAQs